Cytokinetics, Inc. Files 10-Q for Period Ending March 31, 2024

TL;DR

<b>Cytokinetics, Inc. filed its Q1 2024 10-Q report, detailing financial performance and operational updates.</b>

AI Summary

CYTOKINETICS INC (CYTK) filed a Quarterly Report (10-Q) with the SEC on May 10, 2024. Cytokinetics, Inc. filed a 10-Q report for the period ending March 31, 2024. The filing details financial information and business operations for the first quarter of 2024. Key dates and agreements, including royalty agreements and loan agreements, are referenced. The report mentions various share-based compensation awards and their terms. Financial instruments and their fair value measurements are also included.

Why It Matters

For investors and stakeholders tracking CYTOKINETICS INC, this filing contains several important signals. This 10-Q provides investors with the latest financial health and operational status of Cytokinetics, Inc. for the first quarter of 2024. Understanding the details within this filing is crucial for assessing the company's progress on its drug development pipeline and financial commitments.

Risk Assessment

Risk Level: medium — CYTOKINETICS INC shows moderate risk based on this filing. The company's financial disclosures, including details on debt and equity, along with various agreements and compensation plans, require careful review to assess its financial stability and future prospects.

Analyst Insight

Review the detailed financial statements and risk factors in the 10-Q to understand Cytokinetics' current financial position and potential future performance.

Key Numbers

• 2024-03-31 — Period End Date (CONFORMED PERIOD OF REPORT)
• 2024-05-10 — Filing Date (FILED AS OF DATE)
• 2024-01-01 — Quarter Start Date (Reporting Period)
• 2023-03-31 — Prior Year Quarter End (Reporting Period)

Key Players & Entities

• CYTOKINETICS INC (company) — FILER
• 0000950170-24-057805 (other) — ACCESSION NUMBER
• 20240331 (date) — CONFORMED PERIOD OF REPORT
• 20240510 (date) — FILED AS OF DATE
• 0001061983 (company) — CENTRAL INDEX KEY
• 2834 (other) — STANDARD INDUSTRIAL CLASSIFICATION
• 350 OYSTER POINT BOULEVARD (address) — BUSINESS ADDRESS
• SOUTH SAN FRANCISCO (location) — BUSINESS ADDRESS CITY

FAQ

Key Dates

• 2024-03-31: Period End Date — End of the reporting quarter for the 10-Q filing.
• 2024-05-10: Filing Date — Date the 10-Q report was officially filed with the SEC.

Glossary

10-Q

A quarterly report required by the U.S. Securities and Exchange Commission (SEC). (Provides investors with an update on the company's financial performance and operational status during the quarter.)

Royalty Agreements

Contracts where a company receives payments based on sales or usage of a product or technology. (Indicates potential revenue streams or financial obligations related to intellectual property.)

Share-Based Compensation

Compensation provided to employees in the form of stock options, restricted stock units, or performance shares. (Impacts employee incentives, dilution, and the company's expense structure.)

Key Financial Figures

• $0.001 — : Title of each class Common Stock, $0.001 par value Trading symbol CYTK Nam

Filing Documents

• cytk-20240331.htm (10-Q) — 1961KB
• cytk-ex10_1.htm (EX-10.1) — 40KB
• cytk-ex10_2.htm (EX-10.2) — 38KB
• cytk-ex31_1.htm (EX-31.1) — 14KB
• cytk-ex31_2.htm (EX-31.2) — 15KB
• cytk-ex32_1.htm (EX-32.1) — 8KB
• img197571864_0.jpg (GRAPHIC) — 7KB
• 0000950170-24-057805.txt (&nbsp;) — 7544KB
• cytk-20240331.xsd (EX-101.SCH) — 1227KB
• cytk-20240331_htm.xml (XML) — 1039KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION 7

Financial Statements (Unaudited)

Item 1. Financial Statements (Unaudited) 7 Condensed Consolidated Balance Sheets 7 Condensed Consolidated Statements of Operations and Comprehensive Loss 8 Condensed Consolidated Statements of Stockholders' Deficit 9 Condensed Consolidated Statements of Cash Flows 10 Notes to Condensed Consolidated Financial Statements 11

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 21

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 37

Controls and Procedures

Item 4. Controls and Procedures 37

OTHER INFORMATION

PART II. OTHER INFORMATION 38

Legal Proceedings

Item 1. Legal Proceedings 38

Risk Factors

Item 1A. Risk Factors 38

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 68

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 68

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 68

Other Information

Item 5. Other Information 68

Exhibits

Item 6. Exhibits 70

SIGNATURES

SIGNATURES 72 2 Table of Contents Glossary of Terms Unless the context requires otherwise, references to "Cytokinetics," "the Company," "we," "us" or "our" in this Quarterly Report on Form 10-Q refer to Cytokinetics, Incorporated and its subsidiaries. References to "Notes" in this Form 10-Q are to the Notes to the Condensed Consolidated Financial Statements in this Form 10-Q. We also have used other specific terms in this Form 10-Q, most of which are explained or defined below: Term/Abbreviation Definition 2004 Plan Cytokinetics' Amended and Restated 2004 Equity Incentive Plan 2020 RTW Transactions The transactions contemplated by the RTW Royalty Purchase Agreement, Ji Xing Aficamten License Agreement and the Common Stock Purchase Agreements, dated July 14, 2020, by and between Cytokinetics and the RTW Investors 2021 RTW Transactions The transactions contemplated by the Ji Xing OM License Agreement and the Common Stock Purchase Agreements, dated December 20, 2021 by and between Cytokinetics and the RTW Investors 2022 RPI Transactions The transactions contemplated by the RP Loan Agreement and the RP Aficamten RPA 2026 Notes Cytokinetics' 4% convertible senior notes due 2026 2027 Indenture Indenture Agreement, dated July 6, 2022, between Cytokinetics and U.S. Bank Trust Company, as trustee 2027 Notes Cytokinetics' 3.50% convertible senior notes due 2027 ACA Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act ACACIA-HCM Assessment Comparing Aficamten to Placebo on Cardiac Endpoints In Adults with Non-Obstructive HCM ACC American College of Cardiology AHA American Heart Association ALS amyotrophic lateral sclerosis (also known as Lou Gehrig's Disease) ALSFRS-R ALS Functional Rating Scale – Revised Amended ATM Facility amended and restated Controlled Equity Offering Sales Agreement Amgen Agreement Collaboration and Option Agreement, dated Decem

FINANCI AL INFORMATION

PART I. FINANCI AL INFORMATION

FINANCI AL STATEMENTS

ITEM 1. FINANCI AL STATEMENTS CYTOKINETICS, INCORPORATED CONDENSED CONSOLIDAT ED BALANCE SHEETS (In thousands) (Unaudited) March 31, 2024 December 31, 2023 ASSETS Current assets: Cash and cash equivalents $ 119,976 $ 113,024 Short-term investments 498,985 501,800 Accounts receivable 834 1,283 Prepaid expenses and other current assets 18,909 11,944 Total current assets 638,704 628,051 Long-term investments 15,376 40,534 Property and equipment, net 68,018 68,748 Operating lease right-of-use assets 78,170 78,987 Other assets 7,814 7,996 Total assets $ 808,082 $ 824,316 LIABILITIES AND STOCKHOLDERS' DEFICIT Current liabilities: Accounts payable $ 12,967 $ 21,507 Accrued liabilities 40,123 42,641 Short-term operating lease liabilities 18,230 17,891 Current portion of long-term debt 11,520 10,080 Other current liabilities 6,015 10,559 Total current liabilities 88,855 102,678 Term loan, net 56,822 58,384 Convertible notes, net 549,790 548,989 Liabilities related to revenue participation right purchase agreements, net 390,219 379,975 Long-term operating lease liabilities 118,554 120,427 Other non-current liabilities 2 186 Total liabilities 1,204,242 1,210,639 Commitments and contingencies Stockholders' deficit: Preferred stock — — Common stock 105 102 Additional paid-in capital 1,852,155 1,725,823 Accumulated other comprehensive loss ( 539 ) ( 10 ) Accumulated deficit ( 2,247,881 ) ( 2,112,238 ) Total stockholders' deficit ( 396,160 ) ( 386,323 ) Total liabilities and stockholders' deficit $ 808,082 $ 824,316 The accompanying notes are an integral part of these condensed consolidated financial statements. 7 Table of Contents CYTOKINETICS, INCORPORATED CONDENSED CONSOLIDATED STATEMENTS O F OPERATIONS AND COMPREHENSIVE LOSS (In thousands, excep

View Full Filing

View this 10-Q filing on SEC EDGAR